K082033

JUL 31 2008

510(k) Summary

Global USA Distribution, LLC
NannoLight Intense Pulsed Light System
510(k) Premarket Notification

Submitter:	Global USA Distribution, LLC
Address:	10723 Aquila Av. S. Minneapolis, MN 55438
Contact Person:	Matt Makousky
Telephone:	952-703-5373
Facsimile:	952-888-8887
Date Prepared:	April 1, 2008
Device Trade Name:	NannoLight Intense Pulsed Light System
Classification Name:	Instrument, Powered, Laser 79-GEX, 21 CFR 878.4810
Legally Marketed Predicate Devices:	Sciton Profile BBL System (K032460), Lumenis Family of Intense Pulsed-Light (IPL) and IPL/Nd:YAG Laser Systems (K020839)

Description of the NannoLight Intense Pulsed Light System:

The NannoLight Intense Pulsed Light System is composed of a console which houses a power supply, electronic circuit board, cooling system, a liquid crystal display screen (LCD) which displays the settings of power, pulse width, and pulse count which are manually adjusted by a touch screen display panel, a handpiece which contains the light source connected to the console by a power cord, and an on/off footswitch. The NannoLight Intense Pulsed Light System is not battery operated, but is controlled and operated with the aid of computer software.

Intended Use of the NannoLight Intense Pulsed Light System:

The NannoLight Intense Pulsed Light System is indicated for use in surgical, aesthetic and cosmetic applications requiring selective photothermolysis (photocoagulation or coagulation) and hemostasis of soft tissue in the medical specialties of general and plastic surgery and dermatology.

530 - 1400 nm wavelength is indicated for Fitzpatrick skin types I-V for the treatment of:
* Benign pigmented lesions including dyschromia, hyperpigmentation, melasma, and epheleides (freckles)
* Benign cutaneous lesions including warts, scars, and striae

560 - 1400 nm wavelength is indicated for Fitzpatrick skin types I-V for the treatment of:
* Benign cutaneous vascular lesions, including port wine stains, hemangiomas, facial, truncal and leg telangiectasias, rosacea, melasma, angiomas and spider angiomas, poikiloderma of Civatte, leg veins and venous malformations.
* Benign cutaneous lesions including warts, scars, and striae

585 - 1400 nm wavelength is indicated for Fitzpatrick skin types I-V for the treatment of:
* Benign cutaneous vascular lesions, including port wine stains, hemangiomas, facial, truncal and leg telangiectasias, rosacea, melasma, angiomas and spider angiomas, poikiloderma of Civatte, leg veins and venous malformations.
* Benign cutaneous lesions including warts, scars, and striae

640 - 1400 nm wavelength is indicated for Fitzpatrick skin types I-IV for the treatment of:
* The removal of unwanted hair, and to effect stable long-term, or permanent, hair reduction

690 - 1400 nm wavelength is indicated for Fitzpatrick skin types IV and V for the treatment of:
* The removal of unwanted hair, and to effect stable long-term, or permanent, hair reduction

Nonclinical Performance Data:	None
Clinical Performance Data:	None
Additional Information:	None requested at this time
Conclusion:	The NannoLight Intense Pulsed Light System is substantially equivalent to other existing legally marketed laser systems currently in commercial distribution.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Global USA Distribution, LLC
% Underwriters Laboratories, Inc.
Mr. Ned Devine
333 Pfingsten Road
Northbrook, Illinois 60062-2096

JUL 31 2008

Re: K082033
Trade/Device Name: NannoLight Intense Pulsed Light System
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology
Regulatory Class: II
Product Code: GEX
Dated: July 15, 2008
Received: July 17, 2008

Dear Mr. Devine:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K082033

Device Name: NannoLight Intense Pulsed Light System

Indications for Use:

The NannoLight Intense Pulsed Light System is indicated for use in surgical, aesthetic and cosmetic applications requiring selective photothermolysis (photocoagulation or coagulation) and hemostasis of soft tissue in the medical specialties of general and plastic surgery and dermatology.

530 - 1400 nm wavelength is indicated for Fitzpatrick skin types I-V for the treatment of:
* Benign pigmented lesions including dyschromia, hyperpigmentation, melasma, and epheleides (freckles)
* Benign cutaneous lesions including warts, scars, and striae

560 - 1400 nm wavelength is indicated for Fitzpatrick skin types I-V for the treatment of:
* Benign cutaneous vascular lesions, including port wine stains, hemangiomas, facial, truncal and leg telangiectasias, rosacea, melasma, angiomas and spider angiomas, poikiloderma of Civatte, leg veins and venous malformations.
* Benign cutaneous lesions including warts, scars, and striae

585 - 1400 nm wavelength is indicated for Fitzpatrick skin types I-V for the treatment of:
* Benign cutaneous vascular lesions, including port wine stains, hemangiomas, facial, truncal and leg telangiectasias, rosacea, melasma, angiomas and spider angiomas, poikiloderma of Civatte, leg veins and venous malformations.
* Benign cutaneous lesions including warts, scars, and striae

640 - 1400 nm wavelength is indicated for Fitzpatrick skin types I-IV for the treatment of:
* The removal of unwanted hair, and to effect stable long-term, or permanent, hair reduction

690 - 1400 nm wavelength is indicated for Fitzpatrick skin types IV and V for the treatment of:
* The removal of unwanted hair, and to effect stable long-term, or permanent, hair reduction

Prescription Use: ____X____ AND/OR Over-The-Counter Use _____
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(Please do not write below this line – Continue on another page if needed)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of General, Restorative, and Neurological Devices

510(k) Number K082033